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Background: This double-blind, controlled study
107007/NCT00344318) evaluated the immune responses of
he candidate vaccine, PHiD-CV (GlaxoSmithKline Biologi-
als), designed to protect infants against pneumococcal and
on-typeable Haemophilus inﬁuenzae diseases, following
o-administration with DTPw-HBV/Hib +OPV at 6-10-14
eeks of age (EPI schedule) in the Philippines.
Methods: 400 healthy Filipino infants 6 to 12 weeks
f age were randomized (3:1) to receive either PHiD-CV
r licensed 7vCRM vaccine (PrevenarTM/PrevnarTM) co-
dministered with DTPw-HBV/Hib +OPV. Vaccine immune
esponses were assessed one month post-dose III (22F-
nhibition ELISA, ELISA, micro-neutralization assays).
Results: For each of the pneumococcal serotypes
ommon between both vaccines, observed percentages
f infants with antibody concentration ≥0.2g/mL were
ithin the same range for both groups (PHiD-CV group:
91.2%; 7vCRM group: ≥86.3%). At least 99.6% of PHiD-CV
accinees had antibody concentrations ≥0.2g/mL against
neumococcal serotypes 1, 5 and 7F. Anti-pneumococcal
eometric mean antibody concentrations were within the
S
(
(
b
201-9712/$32.00 © 2008 Published by Elsevier Ltd.
oi:10.1016/j.ijid.2008.05.002ame range for both vaccines except for serotypes 18C
nd 19F for which higher immune responses were observed
n the PHiD-CV group. Moreover, immune responses of
ll co-administered vaccines were in line with previous
bservations, with the exception of responses against polio
irus types 1 and 3 which seemed lower in the 7vCRM
roup. Based on these immunogenicity results, PHiD-CV
ould potentially prevent 79% of IPD in Filipino infants
ompared to 62% for 7vCRM (abstract# 3.003), reﬂecting
he importance of the additional serotypes (especially 1
nd 5) for IPD in the Philippines.
Conclusions: PHiD-CV elicited high immune responses for
ach of the 10 pneumococcal vaccine serotypes in infants
accinated according to the 6-10-14 week’s schedule. No
vidence of negative immunological interference beiween
HiD-CV and co-administered vaccines was observed.
oi:10.1016/j.ijid.2008.05.003
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ypeable Haemophilus inﬂuenzae Protein D-Conjugate
accine (PHiD-CV) on Invasive Pneumococcal Disease (IPD)
n Middle East and Asian Countries
.P. Hausdorff1, F. Beckers1, R. Dagan2, N. Begg3,∗, S.
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Background: The candidate PHiD-CV vaccine (Glaxo-
mithKline Biologicals), contains 3 additional serotypes
1, 5, 7F) in comparison to the licensed 7vCRM vaccine
PrevenarTM/PrevnarTM).
Methods: Public health impact of PHiD-CV was estimated
ased on serotype-speciﬁc vaccine effectiveness (SSVE) val-
